期刊
EUROPEAN JOURNAL OF HAEMATOLOGY
卷 93, 期 3, 页码 179-186出版社
WILEY
DOI: 10.1111/ejh.12356
关键词
Sokal score; Hasford score; European Treatment and Outcome Study score; prognostic risk scores; chronic myeloid leukemia; tyrosine kinase inhibitors
类别
资金
- Novartis Pharmaceuticals
The approval of multiple tyrosine kinase inhibitors targeting BCR-ABL has broadened the number of available therapeutic options for chronic myeloid leukemia in the chronic phase (CML-CP). This provides an impetus for optimizing prognostic risk score systems that can guide treatment decisions. Presently, three risk scores-the Sokal, Hasford, and European Treatment and Outcome Study (EUTOS) metrics-have been implemented clinically in CML-CP. While these three formulations all endeavor to gauge likely disease course, they differ from one another in several important respects, with potential implications for prognosis and therapy. Here, we review these risk scores and propose how prognostic systems in CML-CP might be refined to direct patients to optimally effective therapies as efficiently and accurately as possible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据